The Hydropothecary Corporation (TSXV:THCX) announced an agreement with Segra International to use “plant tissue culture propagation into the cannabis plant production process.”
As quoted in the press release:
Segra’s expertise and unique tissue culture technique will allow Hydropothecary to increase its yield of healthy, top-quality plants to serve the growing medical and recreational cannabis markets.
“Working with Segra will allow us to meet one of the biggest challenges as we meet the demand for cannabis products across Canada and beyond, balancing quality and quantity in our cannabis production,” said Sebastien St-Louis, Hydropothecary’s CEO and co-founder. “Thanks to Segra’s plant tissue culture technique, we will scale up our production process while maintaining the industry-leading quality standards that have made us so successful.”
Segra specializes in industrial-scale cannabis micropropagation, also known as plant tissue culture. This process replaces traditional cloning from mother plants with rapid, sterile production of robust and healthy plantlets. It generates exact copies of the original plant without the risk of pathogens, fungi, and other issues that can plague other industrial-scale production processes.